DGX Quote, Financials, Valuation and Earnings

Exact Sciences has a net margin of 8.47% compared to Quest Diagnostics's net margin of -121.19%. Quest Diagnostics's return on equity of 12.99% beat Exact Sciences's return on equity of -34.11%.

Quest Diagnostics has a consensus price target of $177.10, signalling upside risk potential of 5.84%. On the other hand Exact Sciences has an analysts' consensus of $68.89 which suggests that it could grow by 57.78%. Given that Exact Sciences has higher upside potential than Quest Diagnostics, analysts believe Exact Sciences is more attractive than Quest Diagnostics.

Quest Diagnostics has a beta of 0.924, which suggesting that the stock is 7.577% less volatile than S&P 500. In comparison Exact Sciences has a beta of 1.248, suggesting its more volatile than the S&P 500 by 24.844%.

Quest Diagnostics has a quarterly dividend of $0.75 per share corresponding to a yield of 1.79%. Exact Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quest Diagnostics pays 38% of its earnings as a dividend. Exact Sciences pays out -- of its earnings as a dividend. Quest Diagnostics's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Quest Diagnostics quarterly revenues are $2.6B, which are larger than Exact Sciences quarterly revenues of $713.4M. Quest Diagnostics's net income of $222M is higher than Exact Sciences's net income of -$864.6M. Notably, Quest Diagnostics's price-to-earnings ratio is 21.76x while Exact Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quest Diagnostics is 1.92x versus 2.91x for Exact Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Illumina has a net margin of 8.47% compared to Quest Diagnostics's net margin of 16.94%. Quest Diagnostics's return on equity of 12.99% beat Illumina's return on equity of -35.09%.

Quest Diagnostics has a consensus price target of $177.10, signalling upside risk potential of 5.84%. On the other hand Illumina has an analysts' consensus of $130.64 which suggests that it could grow by 63.31%. Given that Illumina has higher upside potential than Quest Diagnostics, analysts believe Illumina is more attractive than Quest Diagnostics.

Quest Diagnostics has a beta of 0.924, which suggesting that the stock is 7.577% less volatile than S&P 500. In comparison Illumina has a beta of 1.171, suggesting its more volatile than the S&P 500 by 17.134%.

Quest Diagnostics has a quarterly dividend of $0.75 per share corresponding to a yield of 1.79%. Illumina offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quest Diagnostics pays 38% of its earnings as a dividend. Illumina pays out -- of its earnings as a dividend. Quest Diagnostics's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Quest Diagnostics quarterly revenues are $2.6B, which are larger than Illumina quarterly revenues of $1.1B. Quest Diagnostics's net income of $222M is higher than Illumina's net income of $187M. Notably, Quest Diagnostics's price-to-earnings ratio is 21.76x while Illumina's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quest Diagnostics is 1.92x versus 2.91x for Illumina. Usually stocks with elevated PS ratios are considered overvalued.

Labcorp Holdings has a net margin of 8.47% compared to Quest Diagnostics's net margin of 4.31%. Quest Diagnostics's return on equity of 12.99% beat Labcorp Holdings's return on equity of 9.29%.

Quest Diagnostics has a consensus price target of $177.10, signalling upside risk potential of 5.84%. On the other hand Labcorp Holdings has an analysts' consensus of $273.60 which suggests that it could grow by 18.94%. Given that Labcorp Holdings has higher upside potential than Quest Diagnostics, analysts believe Labcorp Holdings is more attractive than Quest Diagnostics.

Quest Diagnostics has a beta of 0.924, which suggesting that the stock is 7.577% less volatile than S&P 500. In comparison Labcorp Holdings has a beta of 1.122, suggesting its more volatile than the S&P 500 by 12.207%.

Quest Diagnostics has a quarterly dividend of $0.75 per share corresponding to a yield of 1.79%. Labcorp Holdings offers a yield of 1.25% to investors and pays a quarterly dividend of $0.72 per share. Quest Diagnostics pays 38% of its earnings as a dividend. Labcorp Holdings pays out 32.59% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Quest Diagnostics quarterly revenues are $2.6B, which are smaller than Labcorp Holdings quarterly revenues of $3.3B. Quest Diagnostics's net income of $222M is higher than Labcorp Holdings's net income of $143.4M. Notably, Quest Diagnostics's price-to-earnings ratio is 21.76x while Labcorp Holdings's PE ratio is 26.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quest Diagnostics is 1.92x versus 1.49x for Labcorp Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Mettler-Toledo International has a net margin of 8.47% compared to Quest Diagnostics's net margin of 24.14%. Quest Diagnostics's return on equity of 12.99% beat Mettler-Toledo International's return on equity of --.

Quest Diagnostics has a consensus price target of $177.10, signalling upside risk potential of 5.84%. On the other hand Mettler-Toledo International has an analysts' consensus of $1,369.55 which suggests that it could grow by 16.35%. Given that Mettler-Toledo International has higher upside potential than Quest Diagnostics, analysts believe Mettler-Toledo International is more attractive than Quest Diagnostics.

Quest Diagnostics has a beta of 0.924, which suggesting that the stock is 7.577% less volatile than S&P 500. In comparison Mettler-Toledo International has a beta of 1.151, suggesting its more volatile than the S&P 500 by 15.088%.

Quest Diagnostics has a quarterly dividend of $0.75 per share corresponding to a yield of 1.79%. Mettler-Toledo International offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quest Diagnostics pays 38% of its earnings as a dividend. Mettler-Toledo International pays out -- of its earnings as a dividend. Quest Diagnostics's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Quest Diagnostics quarterly revenues are $2.6B, which are larger than Mettler-Toledo International quarterly revenues of $1B. Quest Diagnostics's net income of $222M is lower than Mettler-Toledo International's net income of $252.3M. Notably, Quest Diagnostics's price-to-earnings ratio is 21.76x while Mettler-Toledo International's PE ratio is 29.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quest Diagnostics is 1.92x versus 6.48x for Mettler-Toledo International. Usually stocks with elevated PS ratios are considered overvalued.